On September 20, 2024, Todd Harris, President and Chief Executive Officer of Tyra Biosciences Inc (TYRA, Financial), sold 16,307 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 1,489,620 shares of Tyra Biosciences Inc.
Tyra Biosciences Inc is engaged in the development of precision medicines for patients with genetically defined cancers. The company focuses on addressing treatment gaps by targeting oncogenic drivers.
Over the past year, Todd Harris has sold a total of 116,307 shares and has not made any purchases of the company's stock. This recent sale is part of a broader trend observed over the last year at Tyra Biosciences Inc, where there have been no insider buys but 10 insider sells.
On the day of the sale, shares of Tyra Biosciences Inc were trading at $24.19, giving the company a market cap of approximately $1.28 billion. This valuation reflects the market's assessment of the company's future potential, factoring in various financial metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
This insider sale might be of interest to investors tracking insider behaviors as an indicator of confidence in the company's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
